FDA Has Approved Emergency Use Of Remdesivir To Treat COVID-19

BuzzFeed News has reporters across five continents bringing you trustworthy stories about the impact of the coronavirus. To help keep this news free, become a member and sign up for our newsletter, Outbreak Today.

The FDA approved the experimental drug remdesivir for emergency use to treat COVID-19 on Friday, just days after a preliminary study reported it shortened hospital stays for COVID-19 patients.

In an emergency use approval statement, the FDA’s chief scientist, Denise Hinton, concluded, “It is reasonable to believe that the known and potential benefits of [remdesivir] outweigh the known and potential risks of the drug for the treatment of patients hospitalized with severe COVID-19.”

The approval came just two days after the report of an NIH-sponsored test of the drug. In an experiment on 1,063 patients, the study found that while the drug did not statistically reduce mortality in COVID-19 patients, it did lead to median hospital stays of 11 days, rather than 15 for patients who received a placebo.

News of the approval came from President Donald Trump in an Oval Office announcement on Friday with the CEO of Gilead Sciences, the drug’s maker. Remdesivir is an anti-viral drug that interferes with the reproduction of viruses in cells, originally intended to treat the MERS and SARS coronaviruses.

“I think this really illustrates what can happen in such a short time,” said Deborah Birx of the White House Coronavirus Task Force.

A separate smaller trial of remdesivir in 237 patients published in The Lancet on Wednesday found no clinical benefits to treating COVID-19 patients with the drug, and was halted because it caused a higher percentage of side effects. However, the study did show similar signs of shortening hospital stays, although not to a statistically significant extent. Both studies started in February.

“The bottom line is that we have shown that an anti-viral can affect this virus and that is in and of itself a great advance,” University of Toronto professor Peter Jüni, the editor-in-chief of the journal Trials, told BuzzFeed News. Jüni suggested that larger clinical trials with more patients will show when during an infection patients will benefit the most from infusion with the drug.

  • Dan Vergano is a science reporter for BuzzFeed News and is based in Washington, DC.

    Contact Dan Vergano at [email protected]

    Got a confidential tip? Submit it here.

Source: Read Full Article